Revannasiddaiah S[au] - Search Results

Year	Number of Results
2011	3
2012	23
2013	24
2014	9
2015	13
2016	7
2017	3
2018	3
2019	4
2020	3
2022	1
2024	0

1

Osimertinib in EGFR-Mutated Advanced NSCLC.

Revannasiddaiah S, Devadas SK, Maka VV. Revannasiddaiah S, et al. N Engl J Med. 2020 May 7;382(19):1864. doi: 10.1056/NEJMc2001514. N Engl J Med. 2020. PMID: 32374972 No abstract available.

2

Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer.

Revannasiddaiah S, Gupta I, Devadas SK. Revannasiddaiah S, et al. Chin Clin Oncol. 2019 Oct;8(S1):S13. doi: 10.21037/cco.2019.01.07. Chin Clin Oncol. 2019. PMID: 31684733 Free article. No abstract available.

3

Chemically enhanced radiotherapy: visions for the future.

Revannasiddaiah S, Susheela SP. Revannasiddaiah S, et al. Ann Transl Med. 2016 Feb;4(3):52. doi: 10.3978/j.issn.2305-5839.2015.11.06. Ann Transl Med. 2016. PMID: 26904574 Free PMC article. Review.

4

Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.

Bhardwaj B, Revannasiddaiah S, Bhardwaj H, Balusu S, Shwaiki A. Bhardwaj B, et al. Among authors: revannasiddaiah s. Ann Transl Med. 2016 Feb;4(3):50. doi: 10.3978/j.issn.2305-5839.2015.10.35. Ann Transl Med. 2016. PMID: 26904572 Free PMC article. Review.

5

Nuclear medicine in myeloma: the state of the science and emerging trends.

Sood A, Revannasiddaiah S, Kumar R. Sood A, et al. Among authors: revannasiddaiah s. Hell J Nucl Med. 2011 Jan-Apr;14(1):2-5. Hell J Nucl Med. 2011. PMID: 21512656

6

Müllerian duct anomalies and their effect on the radiotherapeutic management of cervical cancer.

Rastogi M, Revannasiddaiah S, Thakur P, Thakur P, Gupta M, Gupta MK, Seam RK. Rastogi M, et al. Among authors: revannasiddaiah s. Chin J Cancer. 2013 Aug;32(8):434-40. doi: 10.5732/cjc.012.10222. Epub 2013 Feb 19. Chin J Cancer. 2013. PMID: 23419195 Free PMC article. Review.

7

Further clinical interpretation and implications of KEYNOTE-048 findings.

Revannasiddaiah S, Devadas SK, Maka VV, Kilara N. Revannasiddaiah S, et al. Lancet. 2020 Aug 8;396(10248):378. doi: 10.1016/S0140-6736(20)30903-X. Lancet. 2020. PMID: 32771101 No abstract available.

8

Clarifications sought for implications of PORTEC-3 in clinics.

Revannasiddaiah S, Maka VV, Devadas SK. Revannasiddaiah S, et al. Lancet Oncol. 2019 Nov;20(11):e607. doi: 10.1016/S1470-2045(19)30534-0. Lancet Oncol. 2019. PMID: 31674312 No abstract available.

9

Tumour growth kinetics as a potential predictive and prognostic factor in carcinoma of the lung.

Revannasiddaiah S, Maka VV, Devadas SK. Revannasiddaiah S, et al. Ann Transl Med. 2019 Jul;7(14):295. doi: 10.21037/atm.2019.07.39. Ann Transl Med. 2019. PMID: 31475165 Free PMC article. No abstract available.

10

Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Revannasiddaiah S, Thakur P, Bhardwaj B, Susheela SP, Madabhavi I. Revannasiddaiah S, et al. J Thorac Dis. 2014 Oct;6(Suppl 5):S502-25. doi: 10.3978/j.issn.2072-1439.2014.05.19. J Thorac Dis. 2014. PMID: 25349702 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

88 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year